FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Guide on Near Infrared Analytical Procedures

FDA releases a final guidance on Development and Submission of Near Infrared Analytical Procedures.

Federal Register

FDA Implementing Fallout from Drug/Device Case

Federal Register notice: FDA announces its implementation of a court decision that ruled the agency is not afforded discretion when a combination prod...

Federal Register

MOU Period Extended for Compounded Drugs

Federal Register notice: FDA extends the period for states to decide whether to sign the final standard memorandum of understanding for compounded dru...

Human Drugs

Spectrum Given Complete Response on Rolontis

FDA sends Spectrum Pharmaceuticals a complete response letter on its BLA for Rolontis (eflapegrastim), citing deficiencies related to manufacturing an...

Medical Devices

Boston Scientific Trial on Pulmonary Embolism Therapy

Boston Scientific begins enrolling in the HI-PEITHO clinical trial to compare its EkoSonic Endovascular System in combination with anticoagulation the...

Human Drugs

Academics Challenge FDA Suicidality Drug Warning

Researchers call on FDA to reconsider class suicide risk warnings for all epilepsy drugs.

Human Drugs

Apexigen Orphan Status for Sarcoma Therapy

FDA grants Apexigen an orphan drug designation for APX005M (sotigalimab) for treating soft tissue sarcoma.

Human Drugs

FDA Touts Use of Real-World Evidence in Prograf Approval

Three FDA officials say the recent approval of Astellas Prograf for a new indication demonstrates that real-world data observational studies can be co...

Human Drugs

FDA Complete Response Letter for Ardelyx Tenapanor NDA

An FDA complete response letter says an Ardelyx NDA for tenapanor did not show sufficient treatment effect to be approved.

Federal Register

Workshop on Pediatric Complex Trial Designs

Federal Register notice: FDA announces a public workshop entitled Advancing the Development of Pediatric Therapeutics Complex Innovative Trial Design...